211 related articles for article (PubMed ID: 35974241)
1. Prevalence of BRCA1 and BRCA2 pathogenic variants in 8627 unselected patients with breast cancer: stratification of age at diagnosis, family history and molecular subtype.
Zang F; Ding X; Chen J; Hu L; Sun J; Zhang J; Xu Y; Yao L; Xie Y
Breast Cancer Res Treat; 2022 Oct; 195(3):431-439. PubMed ID: 35974241
[TBL] [Abstract][Full Text] [Related]
2. Prevalence and Prognostic Role of BRCA1/2 Variants in Unselected Chinese Breast Cancer Patients.
Zhong X; Dong Z; Dong H; Li J; Peng Z; Deng L; Zhu X; Sun Y; Lu X; Shen F; Su X; Zhang L; Gu Y; Zheng H
PLoS One; 2016; 11(6):e0156789. PubMed ID: 27257965
[TBL] [Abstract][Full Text] [Related]
3. Analysis of the pathogenic variants of BRCA1 and BRCA2 using next-generation sequencing in women with familial breast cancer: a case-control study.
Zayas-Villanueva OA; Campos-Acevedo LD; Lugo-Trampe JJ; Hernández-Barajas D; González-Guerrero JF; Noriega-Iriondo MF; Ramírez-Sánchez IA; Martínez-de-Villarreal LE
BMC Cancer; 2019 Jul; 19(1):722. PubMed ID: 31331294
[TBL] [Abstract][Full Text] [Related]
4. Analysis of BRCA1/2 mutation spectrum and prevalence in unselected Chinese breast cancer patients by next-generation sequencing.
Li G; Guo X; Tang L; Chen M; Luo X; Peng L; Xu X; Wang S; Xiao Z; Yi W; Dai L; Wang J
J Cancer Res Clin Oncol; 2017 Oct; 143(10):2011-2024. PubMed ID: 28664449
[TBL] [Abstract][Full Text] [Related]
5. Risks of breast and ovarian cancer for women harboring pathogenic missense variants in BRCA1 and BRCA2 compared with those harboring protein truncating variants.
Li H; Engel C; de la Hoya M; Peterlongo P; Yannoukakos D; Livraghi L; Radice P; Thomassen M; Hansen TVO; Gerdes AM; Nielsen HR; Caputo SM; Zambelli A; Borg A; Solano A; Thomas A; Parsons MT; Antoniou AC; Leslie G; Yang X; Chenevix-Trench G; Caldes T; Kwong A; Pedersen IS; Lautrup CK; John EM; Terry MB; Hopper JL; Southey MC; Andrulis IL; Tischkowitz M; Janavicius R; Boonen SE; Kroeldrup L; Varesco L; Hamann U; Vega A; Palmero EI; Garber J; Montagna M; Van Asperen CJ; Foretova L; Greene MH; Selkirk T; Moller P; Toland AE; Domchek SM; James PA; Thorne H; Eccles DM; Nielsen SM; Manoukian S; Pasini B; Caligo MA; Lazaro C; Kirk J; Wappenschmidt B; Spurdle AB; Couch FJ; Schmutzler R; Goldgar DE; ;
Genet Med; 2022 Jan; 24(1):119-129. PubMed ID: 34906479
[TBL] [Abstract][Full Text] [Related]
6. Germline Mutations in Cancer Susceptibility Genes in a Large Series of Unselected Breast Cancer Patients.
Sun J; Meng H; Yao L; Lv M; Bai J; Zhang J; Wang L; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
Clin Cancer Res; 2017 Oct; 23(20):6113-6119. PubMed ID: 28724667
[No Abstract] [Full Text] [Related]
7. Risk of Late-Onset Breast Cancer in Genetically Predisposed Women.
Boddicker NJ; Hu C; Weitzel JN; Kraft P; Nathanson KL; Goldgar DE; Na J; Huang H; Gnanaolivu RD; Larson N; Yussuf A; Yao S; Vachon CM; Trentham-Dietz A; Teras L; Taylor JA; Scott CE; Sandler DP; Pesaran T; Patel AV; Palmer JR; Ong IM; Olson JE; O'Brien K; Neuhausen S; Martinez E; Ma H; Lindstrom S; Le Marchand L; Kooperberg C; Karam R; Hunter DJ; Hodge JM; Haiman C; Gaudet MM; Gao C; LaDuca H; Lacey JV; Dolinsky JS; Chao E; Carter BD; Burnside ES; Bertrand KA; Bernstein L; Auer PW; Ambrosone C; Yadav S; Hart SN; Polley EC; Domchek SM; Couch FJ
J Clin Oncol; 2021 Nov; 39(31):3430-3440. PubMed ID: 34292776
[TBL] [Abstract][Full Text] [Related]
8. Germline and tumor BRCA1/2 pathogenic variants in Chinese triple-negative breast carcinomas.
Ji G; Bao L; Yao Q; Zhang J; Zhu X; Bai Q; Shao Z; Yang W; Zhou X
J Cancer Res Clin Oncol; 2021 Oct; 147(10):2935-2944. PubMed ID: 34254208
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive analysis of BRCA1 and BRCA2 germline mutations in a large cohort of 5931 Chinese women with breast cancer.
Zhang J; Sun J; Chen J; Yao L; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
Breast Cancer Res Treat; 2016 Aug; 158(3):455-62. PubMed ID: 27393621
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of specific and recurrent/founder pathogenic variants in BRCA genes in breast and ovarian cancer in North Africa.
ElBiad O; Laraqui A; El Boukhrissi F; Mounjid C; Lamsisi M; Bajjou T; Elannaz H; Lahlou AI; Kouach J; Benchekroune K; Oukabli M; Chahdi H; Ennaji MM; Tanz R; Sbitti Y; Ichou M; Ennibi K; Badaoui B; Sekhsokh Y
BMC Cancer; 2022 Feb; 22(1):208. PubMed ID: 35216584
[TBL] [Abstract][Full Text] [Related]
11. Germline variants profiling of BRCA1 and BRCA2 in Chinese Hakka breast and ovarian cancer patients.
Zhang Y; Wu H; Yu Z; Li L; Zhang J; Liang X; Huang Q
BMC Cancer; 2022 Aug; 22(1):842. PubMed ID: 35918668
[TBL] [Abstract][Full Text] [Related]
12. [Application of next-generation sequencing in detection of BRCA1/2 and homologous recombination repair pathway multi-genes germline mutation and correlation analysis].
Chen YL; Zhuo ZL; Liu C; Xie F; Yang ZY; Liu PF; Wang S; Zhao XT
Zhonghua Yu Fang Yi Xue Za Zhi; 2022 Mar; 56(3):302-311. PubMed ID: 35381651
[No Abstract] [Full Text] [Related]
13. Analysis of pathogenic variants in BRCA1 and BRCA2 genes using next-generation sequencing in women with triple negative breast cancer from South India.
Rajagopal T; Seshachalam A; Jothi A; Rathnam KK; Talluri S; Venkatabalasubranian S; Dunna NR
Mol Biol Rep; 2022 Apr; 49(4):3025-3032. PubMed ID: 35020120
[TBL] [Abstract][Full Text] [Related]
14. The spectrum of BRCA1 and BRCA2 mutations and clinicopathological characteristics in Chinese women with early-onset breast cancer.
Chen L; Fu F; Huang M; Lv J; Zhang W; Wang C
Breast Cancer Res Treat; 2020 Apr; 180(3):759-766. PubMed ID: 32072338
[TBL] [Abstract][Full Text] [Related]
15. Prevalence and spectrum of germline rare variants in BRCA1/2 and PALB2 among breast cancer cases in Sarawak, Malaysia.
Yang XR; Devi BCR; Sung H; Guida J; Mucaki EJ; Xiao Y; Best A; Garland L; Xie Y; Hu N; Rodriguez-Herrera M; Wang C; Jones K; Luo W; Hicks B; Tang TS; Moitra K; Rogan PK; Dean M
Breast Cancer Res Treat; 2017 Oct; 165(3):687-697. PubMed ID: 28664506
[TBL] [Abstract][Full Text] [Related]
16. BRCA1 and BRCA2 germline mutations in Chinese Hakka breast cancer patients.
Zhang Y; Wu H; Gan C; Rao H; Wang Q; Guo X
BMC Med Genomics; 2024 Jan; 17(1):3. PubMed ID: 38167124
[TBL] [Abstract][Full Text] [Related]
17. Detection of pathogenic variants in breast cancer susceptibility genes in bilateral breast cancer.
Evans DG; Burghel GJ; Schlecht H; Harkness EF; Gandhi A; Howell SJ; Howell A; Forde C; Lalloo F; Newman WG; Smith MJ; Woodward ER
J Med Genet; 2023 Oct; 60(10):974-979. PubMed ID: 37055167
[TBL] [Abstract][Full Text] [Related]
18. A spectrum of BRCA1 and BRCA2 germline deleterious variants in ovarian cancer in Russia.
Kechin A; Boyarskikh U; Barinov A; Tanas A; Kazakova S; Zhevlova A; Khrapov E; Subbotin S; Mishukova O; Kekeeva T; Demidova I; Filipenko M
Breast Cancer Res Treat; 2023 Jan; 197(2):387-395. PubMed ID: 36367610
[TBL] [Abstract][Full Text] [Related]
19. Comparable frequency of BRCA1, BRCA2 and TP53 germline mutations in a multi-ethnic Asian cohort suggests TP53 screening should be offered together with BRCA1/2 screening to early-onset breast cancer patients.
Lee DS; Yoon SY; Looi LM; Kang P; Kang IN; Sivanandan K; Ariffin H; Thong MK; Chin KF; Mohd Taib NA; Yip CH; Teo SH
Breast Cancer Res; 2012 Apr; 14(2):R66. PubMed ID: 22507745
[TBL] [Abstract][Full Text] [Related]
20. Breast cancer in East Africa: Prevalence and spectrum of germline SNV/indel and CNVs in BRCA1 and BRCA2 genes among breast cancer patients in Tanzania.
Rweyemamu LP; Gültaşlar BK; Akan G; Dharsee N; Namkinga LA; Lyantagaye SL; Yazıcı H; Atalar F
Cancer Med; 2023 Feb; 12(3):3395-3409. PubMed ID: 35908255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
